Skip to main content
. 2010 May 25;4:493–517. doi: 10.2147/opth.s8980

Table 2.

Search: Medline®

  1. randomized controlled trial.pt.

  2. (randomized or randomised).ab,ti.

  3. placebo.ab,ti.

  4. randomly.ab,ti.

  5. trial.ab,ti.

  6. groups.ab,ti.

  7. dt.fs.

  8. or/1–7

  9. exp animals/

  10. exp humans/

  11. 9 not (9 and 10)

  12. 8 not 11

  13. exp clinical trial/

  14. (clin$ adj3 trial$).tw.

  15. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.

  16. placebo$.tw.

  17. random$.tw.

  18. exp experimental design/

  19. exp control group/

  20. 18 or 19 or 16 or 13 or 17 or 15 or 14

  21. angiogenes$.tw.

  22. exp angiogenesis inhibitors/

  23. exp angiogenic factor/

  24. endothelial cell growth facto$.tw.

  25. exp vasculotropin/

  26. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$).tw.

  27. (anti adj2 VEGF$).tw.

  28. (endothelial adj2 growth adj2 factor$).tw.

  29. exp angiogenesis inducing agents/

  30. 27 or 25 or 28 or 21 or 26 or 22 or 24 or 23 or 29

  31. exp diabetic retinopathy/

  32. exp macular edema cystoid/

  33. exp macular degeneration/

  34. (macula$ adj2 edema).tw.

  35. (macula$ adj2 edema).tw.

  36. DME.tw.

  37. DMO.tw.

  38. CME.tw.

  39. CSME.tw.

  40. (macula$ adj2 swell$).tw.

  41. microaneurysm$.tw.

  42. (dilat$ adj2 capillar$).tw.

  43. 35 or 33 or 32 or 39 or 40 or 36 or 41 or 42 or 38 or 34 or 37 or 31

  44. 30 and 43 and 20

  45. from 44 keep 2, 9, 11–12, 15, 22–23, 27... 28

  46. from 45 keep 1, 3, 5, 7, 9–10, 12... 15

  47. from 46 keep 5, 7–9, 12–15 8

  48. from 47 keep 1–3, 5–6 5